Antibody Production & Characterization

The initial screening of hybridomas enables the identification of panels of monoclonal antibodies of interest. The further triage of these panels to identify those exhibiting more specific characteristics, such as binding affinity, species and/or family member cross reactivity, cell based activity and the like, requires significantly more protein than that is available in the small small scale cultures of the initial screening stages.

Aragen Bioscience’s team has expertise in various methods for the scale up of antibody production. The production of the monoclonal antibodies of interest can be performed either by the scale up of the hybridomas themselves or via the cloning and expression of the monoclonal antibody using recombinant techniques. If a recombinant method is chosen, one might also elect to isotype switch the antibody or perhaps generate a human-mouse chimeric molecule should a human Fc domain be required for further efficacy evaluations. Aragen Bioscience’s bioproduction capabilities range from the micro gram to gram scale.


Characterization of monoclonal antibodies and their function is a very complex task. There are various biophysical and molecular techniques (e.g. Affinity to target, stability, aggregation propensity, etc.) as well as efficacy measurements (e.g. ADCC, Growth Inhibition, in vivo models) that may be required. Aragen Bioscience, as an end-to-end provider of antibody discovery services, enable it’s clients and partners the ability to perform such complex studies within a single contract research organization (CRO).

Every antibody is different and Aragen’s scientist have the knowledge and experience to customize a monoclonal antibody characterization program to your specific needs. Please contact us to discuss your project.